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INVITED COMMENTARY
A. Ross Naylor, MD, FRCS, Leicester, United Kingdom
How many of you consider gender when deciding whether
carotid endarterectomy (CEA) might be appropriate in patients
with asymptomatic carotid disease? Chances are, relatively few!
Yet, the Asymptomatic Carotid Atherosclerosis Study (ACAS)
showed no conclusive evidence that surgery conferred benefit in
women, and once perioperative strokes were included, neither did
the Asymptomatic Carotid Surgery Trial (ACST). When the data
from the two trials are combined, the gender differences are
difficult to ignore.1
Two observations from the trials might explain why women
gained less benefit. First, women had a lower natural history of
stroke risk than men. Second, women incurred higher morbidity
and mortality after CEA, a phenomenon common to many cardio-
vascular operations. Accordingly, the overall benefit fromCEAwill
be diminished. So should all asymptomatic women now be denied
surgery? Definitely not!
It is, however, becoming untenable to simply treat all asymp-
tomatic men and women as if they derived equivalent benefit.
Combined ACAS and ACST data1 indicate that CEA conferred a
twofold reduction in stroke in men (odds ratio, 2.0; 95% confi-
dence interval, 1.5 to 2.8) compared with neutral benefit in
women (OR 1.04; 95% confidence interval, 0.7 to 1.6). However,
because the confidence intervals straddle “1,” there is still a degree
of statistical uncertainty. It is inevitable, therefore, that certain
womenwill gain considerable benefit from surgery, but can they be
identified?
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Hellings et al have reported one of the first studies to correlate
plaque biology with symptom status and gender. They hypothe-
size that thromboembolic stroke may be less likely to occur in
women because their plaques exhibit features that are less likely to
predispose them to acute plaque disruption, including reduced fat,
less macrophage activity, more smooth muscle cells, higher colla-
gen, and reduced interleukin-8 and matrix metalloproteinase-8
expression, with “asymptomatic women demonstrating the high-
est prevalence of stable plaques.”
These are important observations, despite the unexpected
finding that surface thrombus was unrelated to gender, but do
their data support the statement that “selecting patients for CEA
based on plaque characteristics may hold promise for the future?”
Readers of the Journal of Vascular Surgery will have heard this
Holy Grail being quoted many times during the last 20 years! The
fundamental problem remains that no one has successfully trans-
lated postoperative histologic/biochemical features into preopera-
tive plasma markers or ultrasound/magnetic resonance imaging
parameters that can then reliably and accurately identify the high-
risk patient sitting in the outpatient clinic. This is largely because
few unbiased asymptomatic cohorts are now available for testing
the Helling and colleagues’ hypothesis.
There is, however, a potential solution. There are plans to
undertake randomized trials comparing CEA with angioplasty.
One, the Transatlantic Asymptomatic Carotid Intervention Trial
(TACIT), intends to include “best medical therapy” as a third
limb, largely because many believe pharmacotherapy to have ad-
vanced considerably since ACAS and ACST were recruiting. Pa-
tients randomized in this trial could undergo preoperative assess-
ment of plasma markers and ultrasound/magnetic resonance
imaging so that the Helling and colleagues’ hypothesis can be
tested. Surgical patients would provide samples for histologic and
biochemical analysis, whilst medically treated patients would pro-
vide valuable natural history data. This could be the last chance to
determine optimal patient selection on the basis of evidence rather
than dogma.
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